Table 2. Potential targeted chemical drugs for representative mutated genes.

Subtype	Gene	Variant	Disease	Drugs
Poor	TP53	DELETERIOUS MUTATION, MUTATION, TRUNCATING MUTATION, DNA BINDING DOMAIN MUTATION, WILD TYPE, OVEREXPRESSION, ALTERATION, CONSERVED DOMAIN MUT, G245S, M237I, R158H, R249S, R280K, R280T, R158L	Head and neck squamous cell carcinoma, esophagus squamous cell carcinoma, precursor B lymphoblastic lymphoma/leukemia, myelodysplastic syndrome, myeloma, oral squamous cell carcinoma, gastric adenocarcinoma, breast cancer, colorectal cancer, esophageal carcinoma, acute myeloid leukemia, adrenocortical carcinoma, non-small cell lung carcinoma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, stomach cancer, stomach carcinoma, cancer, leukemia	Doxorubicin, “Cetuximab, Capecitabine, Oxaliplatin”, “Docetaxel, Selumetinib (AZD6244)”, Docetaxel, Adjuvant Chemotherapy, Pazopanib, Alemtuzumab, “Cisplatin, Carboplatin”, Tamoxifen, “Cisplatin, Etoposide, Mitomycin”, EAP Protocol, Nutlin-3a, AMGMDS3, RG7112
	KRAS	G12V, G12D, G12A	Colorectal cancer, lung cancer, lung adenocarcinoma, non-small cell lung carcinoma, pancreatic carcinoma, pancreatic cancer, tumor of exocrine pancreas, hairy cell leukemia, cancer, pancreatic ductal carcinoma, multiple myeloma, melanoma, ovarian cancer	Cetuximab, “Gefitinib, Erlotinib”, “BEZ235 (NVP-BEZ235, Dactolisib), ARRY-142886”, PD0332991, MK-2206, “Docetaxel, Selumetinib (AZD6244)”, Vemurafenib, Crizotinib, Adoptive T-cell Transfer, “Selumetinib (AZD6244), BEZ235”, Panitumumab, Gefitinib, Melphalan, Regorafenib, “Cetuximab, Panitumumab”, “Panitumumab, Cetuximab”
	DNMT3A	R882, MUTATION	Acute myeloid leukemia, T-cell acute lymphoblastic leukemia, myelodysplastic syndrome, cancer	Daunorubicin, Idarubicin, Decitabine, “Atezolizumab, Pembrolizumab, Nivolumab”
Favorable	KIT	D816V	Acute myeloid leukemia, systemic macrocytosis	Midostaurin